^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Melanoma |
| Drug: | plixorafenib (FORE-8394) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
529MO - Activity, safety and circulating tumour DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer
Published date:
09/18/2020
Excerpt:
PLX8394 and cobicistat demonstrated a favorable safety profile and encouraging activity in patients with advanced cancers with BRAF class I and II alterations. Dynamic changes in ctDNA were predictive of clinical outcomes.
